Risk factors for acute kidney injury in adult patients receiving vancomycin

Clinical Drug Investigation

Volumn 34, Issue 3, 2014, Pages 189-193

  Cappelletty, Diane ^a   Jablonski, Alyse ^b   Jung, Rose ^a  

^a UNIVERSITY OF TOLEDO   (United States)

^b Omnicare   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CONTRAST MEDIUM; CREATININE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; GENTAMICIN; HYDROCHLOROTHIAZIDE; RAPAMYCIN; SPIRONOLACTONE; TACROLIMUS; TOBRAMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACUTE KIDNEY FAILURE; ADULT; ANTIBIOTIC THERAPY; ARTICLE; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CREATININE CLEARANCE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEPHROTOXICITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT DURATION; YOUNG ADULT; ACUTE KIDNEY INJURY; AGED; CHEMICALLY INDUCED; DIABETES MELLITUS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

ACUTE KIDNEY INJURY; ADULT; AGED; ANTI-BACTERIAL AGENTS; DIABETES MELLITUS; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; VANCOMYCIN;

EID: 84896834780     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-013-0163-0     Document Type: Article

References (20)

1. Griffith RS. Introduction to vancomycin. Rev Infect Dis. 1981;3(suppl):S200.
2. American Thoracic Society. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388-416.
3. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2009;49(3):325-7.
4. Gurwitz JH, Avorn J, Ros-Degnan D, et al. Nonsteroidal antiinflammatory drug-associated azotemia in the very old. JAMA. 1990;264(4):471-5. (Pubitemid 20223886)
5. Whelton A, Hamilton C. Nonsteroidal anti-inflammatory drugs: effects on kidney function. J Clin Pharmacol. 1991;31(7):588-98.
6. Lapi F, Azoulay L, Yin H, et al. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ. 2013;346:e8525. doi:10.1136/bmj.e8525.
7. Hernandez-Diaz S, Garcia-Rodriguez A. Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugs. Am J Med. 2001;110(3A):20S-7S. (Pubitemid 32155399)
8. Fox CS, Larson MG, Leip E, et al. Predictors of new-onset kidney disease in a community-based population. JAMA. 2004;291(7):844-50. (Pubitemid 38543772)
9. Manjunath G, Tighiouart H, Ibrahim H, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol. 2003;41(1):47-55. (Pubitemid 36044403)
10. Manjunath G, Tighiouart H, Coresh J, et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int. 2003;63(3):1121-9. (Pubitemid 36315592)
11. Perazella MA. Renal vulnerability to drug toxicity. Clin J Am Soc Nephrol. 2009;4(7):1275-83.
12. Guo X, Nzerue R. How to prevent, recognize, and treat drug-induced nephrotoxicity. Cleve Clin J Med. 2002;69(4):289-90.
13. Friedman JH. A recursive partitioning decision rule for non-parametric classification. IEEE Trans Comput. 1977;26(4):404-8.
14. Nishino Y, Takemura S, Minamiyama Y, et al. Targeting superoxide dismutase to renal proximal tubule cells attenuates vancomycin-induced nephrotoxicity in rats. Free Radic Res. 2003;37(4):373-9. (Pubitemid 36240400)
15. Oktem F, Arslan MK, Ozguner F, et al. In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin-induced nephrotoxicity: protection by erdosteine. Toxicology. 2005;215(3):227-33. (Pubitemid 41446325)
16. Cetin H, Olgar S, Oktem F, et al. Novel evidence suggesting an anti-oxidant property for erythropoietin on vancomycin-induced nephrotoxicity in a rat model. Clin Exp Pharmacol Physiol. 2007;34(11):1181-5. (Pubitemid 47416355)
17. Ocak S, Gorur S, Hakverdi S, et al. Protective effects of caffeic acid phenethyl ester, vitamin C, vitamin E and N-acetylcysteine on vancomycin-induced nephrotoxicity in rats. Basic Clin Pharmacol Toxicol. 2007;100(5):328-33. (Pubitemid 46633475)
18. Bosso JA, Nappi J, Rudisill C, et al. Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial. Antimicrob Agents Chemother. 2011;555(12):475-9.
19. Jeffres MN, Isakow W, Doherty JA, et al. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther. 2007;29(6):1107-15. (Pubitemid 47208584)
20. Lodise TP, Patel N, Lomaestro BM, et al. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis. 2009;49(4):507-14.